newsfilter
← Latest News
GlobeNewswire·

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387 Phase 2 data